logo
ProjectForthcoming

Delivering a '1-2 punch' to RAS-driven cancers

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Resistance to current anticancer therapies remains a major public health burden, driving a substantial number of cancer-related deaths in the EU and worldwide. In particular, KRAS-driven lung cancer – one of the most aggressive tumour types – urgently requires new strategies, as resistance to the approved KRAS-G12C inhibitors almost invariably emerges within months after treatment, undermining the

Status
Prospective
Sector
Commercial
Location
Sweden
Updated
19 Nov 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Delivering a '1-2 punch' to RAS-driven cancers

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Delivering a '1-2 punch' to RAS-driven cancers” is an infrastructure initiative in the Commercial sector, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

forthcoming

Taiyo status

Prospective

Taiyo last update

2026-11-19

Contact

Not available for this record.

Description

Description

Resistance to current anticancer therapies remains a major public health burden, driving a substantial number of cancer-related deaths in the EU and worldwide. In particular, KRAS-driven lung cancer – one of the most aggressive tumour types – urgently requires new strategies, as resistance to the approved KRAS-G12C inhibitors almost invariably emerges within months after treatment, undermining their clinical benefit. Mounting evidence highlights that cancer cells can adopt a dynamic and heterogeneous tolerant state early upon treatment, allowing the survival of a small fraction of cancer cells that later fuels resistance and, ultimately, patient relapse. Yet, targeting this tolerant phase remains insufficiently explored to translate to clinical practice that proactively targets cancer resistance. Therefore, RAS-PUNCH aims to overcome this challenge by pioneering a sequential ‘1-2 punch’ strategy that first reprograms and then eliminates tolerant cells in KRAS-driven lung cancer, building on their unique dynamic and heterogeneous nature. Moving beyond conventional strategies, RAS-PUNCH will comprehensively define the phenotypic plasticity underlying RAS inhibitor-induced tolerance, identify small molecule ‘reprogrammers’ through high-throughput phenotypic screening and integrate them into a preclinical ‘1-2 punch’ framework. By delivering the first phenotypic atlas of RAS inhibitor-induced heterogeneity and advancing mechanistically informed ‘1-2 punch’ strategies, RAS-PUNCH addresses a central unmet need in oncology. The expected outcomes will provide proof-of-concept for innovative sequential treatments that prevent resistance in lung cancer, with potential to extend across multiple cancer types. In doing so, the project directly contributes to the EU Cancer Mission’s ambition of saving and improving the lives of cancer patients.

Location

Country

Sweden

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Commercial

Article published date

2026-11-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project